NovaMedica signs the largest SPIC in pharma industry

13 March 2018

GMP News

NovaMedica, a Russian pharmaceutical company and investment project of Rusnano, concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga region.

The SPIC provides for building from scratch a plant for sterile injectable dosage forms. As part of the project, NovaMedica will invest more than three billion rubles to establish the plant. So far, this is the largest SPIC in the Russian pharmaceutical industry in terms of investments.

NovaMedica will build its modern pharmaceutical facility in Vorsino Industrial Park located in the Kaluga region. The facility will be used to localize an extended portfolio of vital and essential drugs of Pfizer, a strategic partner of NovaMedica, and manufacture medicines designed under NovaMedica’s own R&D program. The plant will be established in full compliance with the most stringent international and Russian quality standards, including EU GMP. In the future, this will enable NovaMedica to export some of its products to international markets, which is one of the terms set forth by this SPIC. As part of investment project, the company will create about 300 high-tech jobs.

The plant will manufacture socially important medicines that are demanded in Russian clinics. This includes injection drugs for the treatment of cancer, including, in children, medicines for general anesthesia, hemostatic drugs, medicinal products for inflammatory diseases and severe bacterial and fungal infections.

According to the Russian Ministry of Industry and Trade, overall, the special investment contracts, including the SPIC signed by NovaMedica, attracted more than 9.3 billion rubles of investments into the Russian pharmaceutical industry.

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more